Search - tctmd.com

Displaying 161 - 180 of 626

Sort: Relevancy | Date

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

Todd Neale

October 26, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

Presentation TCT 2015

Is There a Role for Oral Anticoagulants After PCI?

Presenter: Eric R. Bates, Neal S. Kleiman, C. Michael Gibson

October 15, 2015

Presentation TCT 2015

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Presenter: Eric R. Bates, Neal S. Kleiman, Ori Ben-Yehuda

October 15, 2015

Presentation TCT 2015

Should You Bridge in Stented Patients Needing Surgery?

Presenter: Eric R. Bates, Neal S. Kleiman, David F. Kong

October 15, 2015

Presentation TCT 2015

What Is the Optimal Anticoagulant for Transradial PCI?

Presenter: Olivier F. Bertrand, John A. Bittl

October 15, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

Presenter: Nick Curzen, Ajay J. Kirtane, David J. Cohen

October 12, 2015

News Conference News TCT 2015

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

October 12, 2015

Presentation TCT 2015

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

Presenter: Russell A. Brandwein, Elizabeth M Perpetua

October 11, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

Todd Neale

October 11, 2015

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Nicole Lou

October 11, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

L.A. McKeown

October 08, 2015

News Daily News

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

L.A. McKeown

October 08, 2015

News Daily News

Transradial PCI May Attenuate Bivalirudin Benefits

Todd Neale

October 05, 2015

Advertisement

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

My Takeaways From TCT 2015

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

Is There a Role for Oral Anticoagulants After PCI?

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Should You Bridge in Stented Patients Needing Surgery?

What Is the Optimal Anticoagulant for Transradial PCI?

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Discussion Highlights Merits, Limitations of Small Trials

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

I Dont Believe Bivalirudin Should Routinely Be Used as the First-line Anticoagulant in Primary PCI!

LAA Closure Trials Illustrate Evolution of Devices, Trial Design

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

Use of LAA Occlusion in Low-Risk Patients Debated

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

Transradial PCI May Attenuate Bivalirudin Benefits

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content